|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM217B |
Gene summary for FAM217B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM217B | Gene ID | 63939 |
| Gene name | family with sequence similarity 217 member B | |
| Gene Alias | C20orf177 | |
| Cytomap | 20q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NTX9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 63939 | FAM217B | P24T-E | Human | Esophagus | ESCC | 5.81e-09 | 1.96e-01 | 0.1287 |
| 63939 | FAM217B | P26T-E | Human | Esophagus | ESCC | 3.02e-43 | 8.23e-01 | 0.1276 |
| 63939 | FAM217B | P27T-E | Human | Esophagus | ESCC | 9.06e-09 | 1.60e-01 | 0.1055 |
| 63939 | FAM217B | P28T-E | Human | Esophagus | ESCC | 9.45e-25 | 4.59e-01 | 0.1149 |
| 63939 | FAM217B | P30T-E | Human | Esophagus | ESCC | 5.10e-17 | 5.97e-01 | 0.137 |
| 63939 | FAM217B | P31T-E | Human | Esophagus | ESCC | 1.10e-20 | 3.60e-01 | 0.1251 |
| 63939 | FAM217B | P32T-E | Human | Esophagus | ESCC | 7.47e-07 | 1.64e-01 | 0.1666 |
| 63939 | FAM217B | P36T-E | Human | Esophagus | ESCC | 1.48e-15 | 6.44e-01 | 0.1187 |
| 63939 | FAM217B | P37T-E | Human | Esophagus | ESCC | 3.50e-10 | 2.42e-01 | 0.1371 |
| 63939 | FAM217B | P39T-E | Human | Esophagus | ESCC | 6.27e-14 | 2.56e-01 | 0.0894 |
| 63939 | FAM217B | P42T-E | Human | Esophagus | ESCC | 9.53e-10 | 2.88e-01 | 0.1175 |
| 63939 | FAM217B | P44T-E | Human | Esophagus | ESCC | 3.73e-05 | 1.75e-01 | 0.1096 |
| 63939 | FAM217B | P47T-E | Human | Esophagus | ESCC | 2.94e-12 | 2.49e-01 | 0.1067 |
| 63939 | FAM217B | P48T-E | Human | Esophagus | ESCC | 2.29e-08 | 2.09e-01 | 0.0959 |
| 63939 | FAM217B | P49T-E | Human | Esophagus | ESCC | 1.19e-09 | 6.49e-01 | 0.1768 |
| 63939 | FAM217B | P52T-E | Human | Esophagus | ESCC | 7.63e-23 | 6.49e-01 | 0.1555 |
| 63939 | FAM217B | P54T-E | Human | Esophagus | ESCC | 6.60e-13 | 3.64e-01 | 0.0975 |
| 63939 | FAM217B | P56T-E | Human | Esophagus | ESCC | 5.34e-07 | 6.80e-01 | 0.1613 |
| 63939 | FAM217B | P57T-E | Human | Esophagus | ESCC | 9.27e-06 | 2.12e-01 | 0.0926 |
| 63939 | FAM217B | P61T-E | Human | Esophagus | ESCC | 8.23e-15 | 3.81e-01 | 0.099 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM217B | SNV | Missense_Mutation | novel | c.475N>T | p.Ala159Ser | p.A159S | Q9NTX9 | protein_coding | deleterious(0.01) | possibly_damaging(0.783) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
| FAM217B | SNV | Missense_Mutation | c.1081N>T | p.His361Tyr | p.H361Y | Q9NTX9 | protein_coding | tolerated(1) | benign(0.001) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| FAM217B | SNV | Missense_Mutation | c.122C>A | p.Thr41Asn | p.T41N | Q9NTX9 | protein_coding | tolerated(0.08) | benign(0.025) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| FAM217B | SNV | Missense_Mutation | c.42G>T | p.Lys14Asn | p.K14N | Q9NTX9 | protein_coding | deleterious(0) | possibly_damaging(0.803) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD | |
| FAM217B | insertion | Nonsense_Mutation | novel | c.330_331insTTCTGGCAGTTGTTAGCAGAATTATAATTTTGAGTAAGTCCTTT | p.Thr111PhefsTer9 | p.T111Ffs*9 | Q9NTX9 | protein_coding | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| FAM217B | SNV | Missense_Mutation | c.382G>A | p.Asp128Asn | p.D128N | Q9NTX9 | protein_coding | tolerated(0.12) | possibly_damaging(0.503) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
| FAM217B | SNV | Missense_Mutation | c.268N>T | p.Asp90Tyr | p.D90Y | Q9NTX9 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM217B | SNV | Missense_Mutation | c.1101N>C | p.Glu367Asp | p.E367D | Q9NTX9 | protein_coding | tolerated(0.3) | benign(0.136) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM217B | SNV | Missense_Mutation | c.1069N>A | p.Glu357Lys | p.E357K | Q9NTX9 | protein_coding | deleterious(0.01) | benign(0.023) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FAM217B | SNV | Missense_Mutation | c.586N>A | p.Val196Ile | p.V196I | Q9NTX9 | protein_coding | tolerated(0.15) | benign(0.038) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |